SCHEMBL6681366

SCHEMBL6681366

O=C(NCc1ccc(F)cc1)c1ccc2c(c1)C(=O)C(Cc1cccc(F)c1)C(=O)N2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.56
LMNA P02545 5/20 0.56
RXFP1 Q9HBX9 2/20 0.56
THRB P10828 2/20 0.56
CNR1 P21554 1/20 0.48
TP53 P04637 4/20 0.47
POLB P06746 3/20 0.44
ROCK2 O75116 3/20 0.43
ROCK1 Q13464 2/20 0.43
PLK4 O00444 1/20 0.43
CHEK1 O14757 1/20 0.43
AURKA O14965 1/20 0.43
MAPK13 O15264 1/20 0.43
PDPK1 O15530 1/20 0.43
DAPK3 O43293 1/20 0.43
DYRK3 O43781 1/20 0.43
RPS6KA5 O75582 1/20 0.43
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43
CHEK2 O96017 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6679778 0.92 MAPT (0.47) MAPTLMNARXFP1THRBCNR1
SCHEMBL6678821 0.91 MAPT (0.53) MAPTLMNARXFP1THRBTP53
SCHEMBL6683273 0.89 MAPT (0.49) MAPTLMNARXFP1THRBCNR1
SCHEMBL6678534 0.88 MAPT (0.48) MAPTLMNARXFP1THRBCNR1
SCHEMBL6684559 0.87 MAPT (0.53) MAPTLMNARXFP1THRBCNR1
SCHEMBL6680500 0.87 MAPT (0.47) MAPTLMNARXFP1THRBCNR1
SCHEMBL6684875 0.87 MAPT (0.49) MAPTLMNARXFP1THRBCNR1
SCHEMBL6680173 0.86 ALDH1A1 (0.53) MAPTLMNARXFP1THRBTP53
SCHEMBL6665695 0.84 NR4A2 (0.43) MAPTLMNARXFP1THRBKMT2A
SCHEMBL6835302 0.80 MAPT (0.46) MAPTLMNARXFP1THRBCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors HICKS JAMES LESTER (US) 2004-03-04 US disclosed
WO-2004014388-A1 6,6-FUSED HETEROARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors MMP13, MMP26, MMP9 MAPT 2365/4885LMNA 2566/4885RXFP1 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.